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Abstract 
Heart failure is a serious cause of morbidity and mortality with many patients 
ultimately requiring heart transplantation. As the rate of heart failure continues to 
increase and surpass the number of available donor hearts, the need for cardiac 
assist devices is rapidly rising. The total artificial heart has emerged as an effective 
therapeutic option in patients with end-stage biventricular heart failure who are 
awaiting orthotopic heart transplantation. The TAH replaces the patient’s native 
ventricle and valves and has one of the highest bridge to transplant rates. Many 
complications have been associated with the TAH including infections, bleeding, 
thrombosis, device malfunction, neurological complications among others. CT is 
the imaging modality of choice that aids in early recognition of TAH complications. 
The aim of this review is to illustrate the TAH components and CT based imaging 
of TAH complications. Recognition of TAH complications can help to plan for early 
intervention and therefore improve patient’s survival. 
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Introduction 
 
Heart failure is recognized as a major health problem [1-3]. According to the 
American Heart Association (AHA), there are approximately 5.8 million of 
Americans with heart failure and 500,000 new cases of heart failure are diagnosed 
each year [1, 2]. The prognosis of heart failure is poor with estimates rates of 
survival of 50% at 5 years and 10% at 10 years [4]. Orthotropic heart 
transplantation has been the definitive form of therapy for patients with end-stage 
biventricular heart failure. However, only 2200 donor hearts are available each 
year [5]. This discrepancy between the clinical need for donor hearts and the 
available supply has led to the development of devices such as the total artificial 
heart (TAH) [1-3, 5, 6]. 
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The Jarvik 7 was the first attempt to artificial implantable hearts, but the recipients 
suffered major complications [7]. The Abiocor TAH was first implanted in humans 
in 2001 in a destination therapy trial of fourteen patients who received this device 
but none of the patients survived in this trial. The Abiocor device has been 
unavailable since then [6]. 
The Syncardia total artificial heart (TAH), formerly CardioWest, is the only 
implantable device approved by the United States Food and Drug Administration 
(FDA) for patients with severe biventricular heart failure [5-12]. Flow rates in the 
Syncardia device are normally 7-9L/min and there is very little turbulence within 
the device [13]. 
The goal of the total artificial heart is to bridge patients to heart transplantation, 
replace failing ventricles, malfunctioning valves and eliminate arrhythmias [5-16].  
Other mechanical circulatory assist devices include short-term cardiac assist 
devices such as the Tandem-Heart percutaneous assist device (Cardiac Assist) 
and the Impella [7,17]. The Tandem-Heart is an extracorporeal continuous flow 
centrifugal assist device used to treat postcardiotomy shock and as to bridge to 
heart transplantation [7,17]. The Impella device is used as a minimally invasive 
option for patients requiring temporary cardiac support for acute heart failure, 
cardiogenic shock or patients undergoing high risk percutaneous interventions to 
avoid hemodynamic instability [18]. 
One of the mainstays for mechanical support for patients with end-stage 
ventricular failure are the ventricular assist devices (VADs). These can be used to 
assist in the function of a single ventricle (RVADs: right ventricular assist devices, 
LVADs: Left ventricular assist devices) or in biventricular failure (BiVAD: 
biventricular assist devices) [17-19].  
The LVADs are used as bridge to heart transplantation, as a bridge to myocardial 
recovery and as destination therapy in patients who are not candidates for heart 
transplant. There are two main categories of LVADs : earlier generation or 
pulsatile flow devices (HeartMateXVE) and late generation or continuous flow 
devices (Jarvik 2000, VentrAssist, HeartMate II, Heartware and HeartMate III) [18-
20]. Continuous devices provide an advantage to their first generation counterpart 
including smaller size, less noise and increased durability and reliability (Table 1) 
[18]. 
Of all these devices, the total artificial heart (Syncardia) has one of the highest 
bridge to transplant rate. It is reported that 79% of patients with the Syncardia TAH 
survive to orthotopic heart transplant [5,11,13]. In a study conducted by Copeland 
et al. survival after Syncardia transplantation at 1, 5 and 10 years was reported to 
be 76.8%, 60.5% and 41.2% respectively [21]. 
There have been more than 1250 implants of the total artificial heart accounting for 
more than 350 patient-years of life with this device [5]. 
Torregrossa et al. have described the use of Syncardia TAH as a destination 
therapy in patients not eligible for heart transplantation [16]. 
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Table 1: First and second generation left ventricular assist devices (LVADs) 
Total Artificial Heart Indications and Contraindications  
Candidates for total artificial heart are those with end-stage biventricular heart 
failure (New York Association functional class IV) who are eligible to receive 
orthotopic heart transplant. The body surface area must be at least 1.7m2 and the 
distance between the posterior cortex of the sternum and anterior cortex of T10 
vertebra should be at least 
10cm (Figure 1) in order to 
accommodate the device 
[5,12,13].Contraindications to 
TAH include transplant 
inedibility, left heart failure in 
absence of right-heart failure, 
high risk for anticoagulation, 
and a small thoracic cavity 
unsuitable to fit the device 
[5,12,13]. Other exclusion 
criteria are: concomitant use of 
another vascular assist device 
and pulmonary vascular 
resistance of equal or greater 
than 8 Wood units [13]. 
Figure 1.The distance 
between the posterior cortex of the sternum and the anterior cortex of T10 
should be at least 10 cm to accommodate the TAH. 
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Total Artificial Heart Components 
The TAH consists of two artificial ventricles and four mechanical valves: two 27 
mm inflow valves (atrioventricular valves) and two 25 mm outflow valves (aortic 
and pulmonic valves). 
Each of the two artificial ventricles (right and left) house four flexible polyurethane 
diaphragms including a seamless blood contacting diaphragm, two intermediate 
diaphragms and an air diaphragm [5,6,12]. 
The artificial left ventricle is connected to the native left atrium by a left atrial 
flexible polyurethane inflow connector (Quickconnect) and to the native aorta by an 
aortic outflow cannula. Similarly, the artificial right ventricle is connected to the 
native right atrium by a right atrial flexible polyurethane inflow connector 
(Quickconnect) and to the native pulmonary aorta by a pulmonary artery outflow 
cannula (Figure 2) [5,6,12]. The two artificial ventricles housing flexible 
polyurethane diaphragms are connected to two pneumatic drivelines. This design 
allows the ventricles to fill and then eject blood when compressed by air from an 
external console [5,12]. 
There are two types of console: a standard bedside console (Big Blue) and a 
portable driver system (Freedom Driver) [5]. The console provides monitoring of 
data such as device rate, stroke volume and cardiac output as well as patient-
related alarms. Each artificial ventricle of the TAH delivers a maximum stroke 
volume of 70mL [5,6]. 
 
Figure 2. Syncardia 
TAH components. 
 
 
 
 
 
 
 
 
 
 
 
 
Total Artificial Heart 
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Implantation 
The native ventricles, ventral surface of the atria, the proximal ascending aorta and 
pulmonary artery are surgically removed. Inflow right and left atrial connectors are 
attached to the native atrial remnants. Likewise, aortic and pulmonic outflow 
connectors are anastomosed with the native thoracic aorta and pulmonary artery. 
The artificial ventricles and pneumatic drivelines are then installed (Figure 3) 
[5,12].  
The native pericardial sac is left open and the TAH implant is enfolded 
polytetrafluoroethylene that functions as neopericardium which favors future 
explantation. A tissue expander (Mentor walled silicone filled with saline) is placed 
between the artificial and left ventricle to avoid contraction of the surgical cavity 
and to facilitate explantation for orthotopic heart transplant [5]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Steps for total artificial heart implantation. A. Failing heart end-
stage biventricular failure. B. Both failing native ventricles are surgically 
removed. C. Excision of the atrioventricular, pulmonic and aortic valves. D. 
Complete removal of the ventricular chambers, ventral atria and proximal 
pulmonary and aorta. E. Right and left atrial inflow connectors 
(Quickconnect) and outflow pulmonary and aortic conduits are inserted. F. 
The two artificial ventricles with pneumatic drivelines are implanted. 
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Total Artificial Heart Imaging Modalities 
Chest radiograph is utilized after TAH implantation to monitor the device and to 
evaluate for potential complications. The TAH mechanical valves are not situated 
in their expected anatomic location on a plain chest radiograph. Moreover, the air-
filled ventricles seen in systole (diaphragm move inwards to empty the ventricles) 
can be mistaken with mediastinal air collections creating potential diagnostic errors 
of interpretation [5].  
Echocardiogram, in particular transesophageal echocardiography (TEE) can be 
used pre-operatively and intraoperatively to establish a baseline to identify future 
valve malfunctions [22]. However, some of the limitation of TEE is the challenging 
evaluation of the aortic valves due to poor transgastric windows and acoustic 
shadowing of the device.  Also, reverberation and ring artifacts generated from the 
TAH mechanical valves can also hinder imaging of the ventricular chambers [22]. 
CT is the modality of choice to assess the TAH (Figure 4) [5].  Contrast can be 
administered in patients who can tolerate the contrast media and those with 
adequate renal function.  For patients who cannot receive contrast, an 
unenhanced CT can be performed [5]. Prospective or retrospective cardiac gating 
is not feasible given that there is no recordable ECG (no QRS complex) [5]. MRI is 
contraindicated due to unsafety which precludes MRI evaluation (Table 2). 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Axial NCCT (A), coronal NCCT 
(B), and Chest radiograph (C) showing 
TAH parts: TV=artificial Tricuspid 
valve; MV=artificial mitral valve; 
RV=artificial right ventricle, 
AV=artificial aortic valve; PV=  
artificially pulmonic valve partially 
seen; LV=artificial left ventricle; PGC= 
pulmonary graft conduit not well seen; 
AGC=Aortic graft conduit; LVPD: left 
ventricle pneumatic driveline; RVPD: 
right ventricle pneumatic driveline; N=     
                                                                neopericardium; TE=tissue expander. 
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Table 2. Imaging modalities of the TAH. 
Therefore, it is important to become familiar with the normal CT appearance of the 
TAH and its components as well as to recognize its complications. 
Total Artificial Heart Complications: 
TAH Infectious complications 
Infectious complications are one of the most common adverse events in TAH 
recipients (53-62%) and may involve the mediastinum, pericardium, driveline and 
respiratory tract (Figures 5-11) [5,14,16]. 
Torregrossa et al. reported driveline infections in 27 % of patients [16] and 
Copeland described postoperative infections in 77% of patients [14]. 
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Figure 5. Infectious complications; 
Mediastinal abscess. A) Axial; B) coronal 
and C) sagittal NCCT show fluid collection 
in the anterior mediastinum (thick arrow) 
with flecks of air (thin arrow) indicating 
abscess. D) Axial and E) NCCT portray 
fluid collection in the anterior 
mediastinum (thick arrow) in a different 
patient. 
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Figure 6. Infectious complications; neopericardium/ intra-cardiac infection. 
A) Axial and B) coronal NCCT depict mediastinal collection (dashed thin 
arrow) with associated disruption of the neo-pericardium (thick arrow) and 
flecks of air (short arrow) caused by pericardial bacterial infection. C) Ill-
defined hyperdensity in the neopericardial fluid (thick arrow) proven to be 
fungal infection. 
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Figure 7 Infectious complications; 
superficial and retrosternal abscess. A) 
Axial and B) Axial NCCT depicts infiltrative 
changes overlying the sternotomy wires 
(thick arrow). C) Axial NCCT performed 2 
weeks later shows a fluid collection 
superficial to the sternotomy wires (short 
arrow) and in the retrosternal space (dashed 
arrow) in the same patient consistent with 
abscess. 
 
 
Figure 8. Infectious complications; infected pericardial fluid. A) Axial and B) 
coronal NCCT demonstrates a fluid collection  (thick arrow) around the 
neopericardium proven to be infected. 
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Figure 9. Infectious complication involving the pneumatic drivelines. A) Axial 
B) Axial and C) coronal NCCT depicts fluid collection (thick arrow) and 
stranding (thin dashed arrow) around the pneumatic drivelines with 
extension into the preperitoneal space (short arrow). 
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Figure 10. Infectious complications; multifocal pneumonia. A) Axial and B) 
sagittal NCCT depicts patchy ground-glass opacities (dashed orange 
arrows) and pleural effusions (short arrow) in this patient with multifocal 
pneumonia. C) Axial NCCT shows patchy airspace opacities bilaterally 
(dashed yellow arrows) representing multifocal pneumonia. Also, there are 
associated diffuse ground-glass opacities (asterisk) consistent with 
overlying pulmonary edema. 
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Figure 11. Infectious complications; septic emboli. A) Axial and B) sagittal 
NCCT portrays nodular opacities (thick arrow) in the bilateral lungs 
consistent with septic emboli. C) Coronal NCCT shows feeding vessel sign 
(dashed arrow) in the same patient consistent with hematogeneous spread 
of infection. 
TAH Hematoma/Bleeding 
Postoperative bleeding occurred in 23% and 62% of TAH recipients in the studies 
conducted by Parker et. al and Copeland et.al respectively. The most common 
sites of bleeding are the mediastinum (hemomediastinum) and thorax 
(hemothorax) (Figures 12-16) [5,14]. Localized right atrial tamponade has been 
described [5,12]. Leprince et al. reported two cases in their study of 127 patients 
[23]. 
The use of anticoagulation can predispose to delayed extrathoracic hemorrhage 
including subarachnoid and retroperitoneal hemorrhage [24]. 
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 Figure 12 TAH mediastinal hematoma. 
A) Axial, B) axial and C) coronal NCCT shows an anterior mediastinal hematoma 
(thick arrow) which compresses and causes deformity of  the right cardiac 
chambers, predominantly of the right atrium (dashed arrow). D) Axial NCCT 
shows evacuation of hematoma. E) Small mediastinal hematoma (thick arrow) in 
a different patient with focus of suture dehiscence (short arrow). 
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Figure 13. Hematoma around the pneumatic drivelines. A) Axial, B) axial ,C) 
coronal and D) sagittal  NCCT depicts high density fluid surrounding the 
pneumatic drivelines (thick arrow) representing hematoma. 
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Figure 14. TAH 
Hemopericardium. A) Axial and 
B) coronal NCCT depicts high 
density fluid representing 
hemopericardium (thick arrow) 
with mass effect on the left 
cardiac chambers. C) NCCT 
shows suture line dehiscence 
in the right atrial chamber (thin 
arrow) which was repaired 
surgically. 
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Figure 15. Retroperitoneal hematoma. A) Axial and B) coronal NCCT shows 
heterogeneous high density collection in the retroperitoneum (thick arrow) 
representing hematoma. 
 
 
 
Figure 16 Pulmonary hemorrhages. A) Chest radiograph shows diffuse 
alveolar opacities (thin dashed arrow). B, C)  Axial and coronal NCCT depicts  
confluent areas of consolidation and diffuse alveolar opacities (thick 
arrows)in the bilateral lungs proven to be pulmonary hemorrhage.  
 
  
 
 
The VAD Journal: http://dx.doi.org/10.13023/VAD.2016.18 Page 18 of 24 
 
The VAD Journal: The journal of mechanical assisted circulation and heart failure 
TAH Thrombosis/Infarct 
The TAH has been associated with significant risk of thrombosis including the lung 
and solid organs (e.g. spleen, kidney) (Figures 17 and 18). Parker et al. reported 
4.5 % cases of acute pulmonary embolism in TAH recipients [5]. Torregrossa et al. 
reported 19% of thromboembolic events in recipients 1 year post-implantation [16].  
In patients with TAH, optimal anticoagulation includes both anticoagulant such as 
warfarin and antiplatelet therapy. 
 
Figure 17. Pulmonary embolism/infarction. A) Axial contrast enhanced CT 
(CECT) shows pulmonary embolism (thick arrow) in the right main 
pulmonary artery extending into the interlobar artery. B) Coronal CECT 
shows wedge shape area of hyperattenuation in the right lung consistent 
with pulmonary infarct (dashed arrow). 
 
 
Figure 18 Solid organ infarcts. A. CECT depicts large splenic infarct (thick 
arrow). B. CECT portrays infarct in the right kidney (thick arrow). 
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TAH Device Malfunction 
The surgical anastomosis between the device components including the great 
vessels and synthetic inflow atrial connectors and great vessel outflow connectors 
may become weak and break down. Surgical dehiscence require immediate repair. 
Other commonly encountered complication occurring with the drivelines are kinks 
and leaks [5]. 
TAH Neurologic Complications 
Leprince et al. reported a low stroke rate in TAH recipient (0.2 events per patient 
per year) [23]. Kirsch et al. have reported 10% cases of stroke in a study 
conducted in 90 patients [25]. Subarachnoid hemorrhage also occurs in patient 
with TAH and is related to anticoagulation therapy (Figure 19) [5]. 
 
 
Figure 19. TAH neurologic complications. A) Non contrast head CT shows 
infarct in the left MCA territory (thick arrow). B) Non contrast CT shows 
subarachnoid hemorrhage (thin arrow) in the bilateral cerebral convexities. 
Other complications seen with the TAH can be due to hypoperfusion and include 
mesenteric ischemia and bowel perforation (Figure 20). 
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Figure 20 Bowel ischemia A) Abdominal radiograph portrays distension of 
small bowel loops (dashed arrow). B) CECT depicts bowel wall thickening 
(thick arrow), mesenteric stranding (thin arrow) and pneumatosis (thin 
dashed arrow) consistent with bowel ischemia. C) CECT in the same patient 
shows air in the superior mesenteric vein and its branches (short arrow). D) 
Sagittal CECT shows pneumatosis (thin dashed arrow), bowel wall 
thickening (thick arrow) and gas in the SMV and portal vein (short arrows) 
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Overload states (Figure 21) such as ascites, anasarca, pulmonary edema and 
effusions have also been described. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21 Ascites, anasarca. A) Axial B) axial and C) coronal  NCCT shows  
fluid in the paracolic gutters and pelvic cavity (thick arrows) as well as 
subcutaneous edema (thin arrow) representing anasarca. 
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Conclusions 
The Syncardia total artificial heart (TAH) is the only implantable device approved 
by the United States Food and Drug administration (FDA) for use in patients 
suffering from biventricular heart failure. It is a device used in patients with end-
stage biventricular heart failure while waiting for orthotopic heart transplantation. 
The most common complications on TAH recipients include infections, bleeding, 
thrombosis, liver failure, renal failure, and neurological events such as stroke and 
device malfunction. Infectious and hemorrhagic complications have been reported 
as major causes of death [5]. 
The role of CT imaging in the recognition of clinical outcomes associated with TAH 
complications is of paramount importance to guide clinicians in early therapeutic 
interventions to improve patient’s survival ultimately yield longer survival times. 
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